Aspect Biosystems

Vancouver’s Aspect Biosystems has raised USD $115 million in Series B funding, advancing its work on bioprinted tissue therapeutics. Led by Dimension and supported by Novo Nordisk, Radical Ventures, InBC, and others, the funding will expand Aspect’s AI-powered bioprinting and therapeutic platform.

The company aims to deliver cellular medicines for metabolic and endocrine diseases, building on partnerships with Novo Nordisk and Canadian governments. CEO Tamer Mohamed lauded the investor support, while Dimension’s Nan Li called Aspect a leader in regenerative medicine. This milestone cements Aspect’s role in biotech innovation and its pursuit of transformative patient care solutions.

Want to know more? Check out the source code on Techcouver.

Vancouver’s Aspect Biosystems announced a $72.75 million investment from the Governments of Canada and British Columbia to support a $200 million project advancing their bioprinted tissue therapeutics. This funding will enhance Aspect’s biomanufacturing capabilities and therapeutic platform, targeting incurable diseases with innovative treatments.

Aspect’s collaboration with Novo Nordisk will be leveraged, focusing on diabetes, obesity, liver disease, and other metabolic disorders. CEO Tamer Mohamed emphasized the investment as a crucial step in regenerative medicine.

Want to know more? Check out the source code on Techcouver.